Geron (GERN) Projected to Post Earnings on Wednesday

Geron (NASDAQ:GERN) is expected to be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $45.29 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Geron Stock Up 2.5 %

GERN opened at $2.63 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The firm’s fifty day moving average price is $3.19 and its two-hundred day moving average price is $3.90. The company has a market capitalization of $1.59 billion, a P/E ratio of -8.20 and a beta of 0.53. Geron has a fifty-two week low of $1.64 and a fifty-two week high of $5.34.

Analysts Set New Price Targets

GERN has been the subject of a number of research analyst reports. Barclays raised Geron to a “strong-buy” rating in a report on Friday, November 29th. Needham & Company LLC boosted their target price on shares of Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Geron in a research report on Tuesday, December 10th. Finally, B. Riley lowered their price target on shares of Geron from $5.50 to $3.50 and set a “buy” rating for the company in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Geron currently has an average rating of “Moderate Buy” and a consensus target price of $6.91.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.